{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:31:53Z","timestamp":1740115913544,"version":"3.37.3"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T00:00:00Z","timestamp":1713657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015318","name":"Montreal Neurological Institute-Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chemical Neuroanatomy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jchemneu.2024.102422","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T01:32:58Z","timestamp":1713835978000},"page":"102422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Autoradiographic labelling of metabotropic glutamate type 2\/3 receptors in the hemi-parkinsonian rat brain"],"prefix":"10.1016","volume":"138","author":[{"given":"Esther","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Frouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Shaqfah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"B\u00e9dard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-8334","authenticated-orcid":false,"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchemneu.2024.102422_bib1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord.\u00a0Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.jchemneu.2024.102422_bib2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mds.25920","article-title":"The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model","volume":"29","author":"Bezard","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jchemneu.2024.102422_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109205","article-title":"A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia","volume":"218","author":"Calabrese","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jchemneu.2024.102422_bib4","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1042\/BST20140006","article-title":"Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease","volume":"42","author":"Cenci","year":"2014","journal-title":"Biochem Soc. Trans."},{"key":"10.1016\/j.jchemneu.2024.102422_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0925s41","article-title":"Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of parkinson's disease in rats and mice","volume":"41","author":"Cenci","year":"2007","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.jchemneu.2024.102422_bib6","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/mds.27462","article-title":"An mGlu4-positive allosteric modulator alleviates parkinsonism in primates","volume":"33","author":"Charvin","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jchemneu.2024.102422_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.64.1.20","article-title":"Circuits and circuit disorders of the basal ganglia","volume":"64","author":"DeLong","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib8","series-title":"International Review of Neurobiology","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/bs.irn.2022.10.002","article-title":"Chapter seven - sex differences and hormonal regulation of metabotropic glutamate receptor synaptic plasticity","author":"Fabian","year":"2023"},{"key":"10.1016\/j.jchemneu.2024.102422_bib9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jchemneu.2024.102422_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.schres.2011.01.008","article-title":"Density of metabotropic glutamate receptors 2 and 3 (mGluR2\/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age","volume":"128","author":"Frank","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jchemneu.2024.102422_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107725","article-title":"Activation of mGlu(2\/3) receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism.","volume":"158","author":"Frouni","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jchemneu.2024.102422_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/nmt-2021-0055","article-title":"Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic","volume":"12","author":"Frouni","year":"2022","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.jchemneu.2024.102422_bib13","doi-asserted-by":"crossref","DOI":"10.1007\/s00221-024-06815-w","article-title":"[(3)H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain.","author":"Frouni","year":"2024","journal-title":"Exp. Brain Res"},{"key":"10.1016\/j.jchemneu.2024.102422_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00221-018-5390-4","article-title":"Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat","volume":"237","author":"Frouni","year":"2019","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.jchemneu.2024.102422_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00702-020-02287-8","article-title":"Effect of the mGlu(2) positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.","volume":"128","author":"Frouni","year":"2021","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jchemneu.2024.102422_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FBP.0000000000000441","article-title":"Classic animal models of Parkinson's disease: a historical perspective","volume":"30","author":"Hamadjida","year":"2019","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib17","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/ejn.14679","article-title":"The highly selective mGlu(2) receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease","volume":"51","author":"Hamadjida","year":"2020","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.jchemneu.2024.102422_bib18","first-page":"511","article-title":"ADS-5102 (Amantadine) extended-release capsules for levodopa-induced Dyskinesia in Parkinson's disease (EASE LID 2 Study): interim results of an open-label safety study","volume":"7","author":"Hauser","year":"2017","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.jchemneu.2024.102422_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jchemneu.2024.102422_bib20","first-page":"19","article-title":"Biochemical pathophysiology of Parkinson's disease","volume":"45","author":"Hornykiewicz","year":"1987","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jchemneu.2024.102422_bib22","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jchemneu.2024.102422_bib23","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00210-023-02458-w","article-title":"Distribution of [11C]-JNJ-42491293 in the marmoset brain: a positron emission tomography study","volume":"396","author":"Kang","year":"2023","journal-title":"Naunyn-schmiede 'S. Arch. Pharmacol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib24","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00210-023-02587-2","article-title":"The mGluR(2\/3) orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset","volume":"396","author":"Kang","year":"2023","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(97)00191-3","article-title":"LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors","volume":"37","author":"Kingston","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jchemneu.2024.102422_bib26","series-title":"Integrated Program in Neuroscience","first-page":"451","article-title":"Towards therapies for Parkinson\u2019s Disease: treatment-related complications and animal models","author":"Kwan","year":"2023"},{"key":"10.1016\/j.jchemneu.2024.102422_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172914","article-title":"Ondansetron, a highly selective 5-HT(3) receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.","volume":"871","author":"Kwan","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108465","article-title":"Combined 5-HT(2A) and mGlu(2) modulation for the treatment of dyskinesia and psychosis in Parkinson's disease.","volume":"186","author":"Kwan","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jchemneu.2024.102422_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107891","article-title":"Defining the homo- and heterodimerization propensities of metabotropic glutamate receptors","volume":"31","author":"Lee","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.jchemneu.2024.102422_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","article-title":"Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"29","author":"Levandis","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jchemneu.2024.102422_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00684378","article-title":"Simultaneous inhibition of endogenous avidin-binding activity and peroxidase applicable for the avidin-biotin system using monoclonal antibodies","volume":"83","author":"Matsumoto","year":"1985","journal-title":"Histochemistry"},{"key":"10.1016\/j.jchemneu.2024.102422_bib32","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.neuron.2019.03.004","article-title":"Circuit mechanisms of Parkinson's disease","volume":"101","author":"McGregor","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.jchemneu.2024.102422_bib33","first-page":"483","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem","volume":"101","author":"Mela","year":"2007"},{"key":"10.1016\/j.jchemneu.2024.102422_bib34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/0006-8993(82)90265-7","article-title":"Chloride ions enhance L-glutamate binding to rat brain synaptic membranes","volume":"243","author":"Mena","year":"1982","journal-title":"Brain Res."},{"key":"10.1016\/j.jchemneu.2024.102422_bib35","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s10072-021-05319-7","article-title":"Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease: a meta-analysis","volume":"42","author":"Negida","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jchemneu.2024.102422_bib36","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0960-894X(98)00329-1","article-title":"3H]LY341495, a highly potent, selective and novel radioligand for labeling Group II metabotropic glutamate receptors","volume":"8","author":"Ornstein","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jchemneu.2024.102422_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104525","article-title":"Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal \u03b1-synuclein preformed fibrils","volume":"130","author":"Patterson","year":"2019","journal-title":"Neurobiol. Dis."},{"year":"2007","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","key":"10.1016\/j.jchemneu.2024.102422_bib38"},{"key":"10.1016\/j.jchemneu.2024.102422_bib39","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00702-018-1869-1","article-title":"Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia","volume":"125","author":"Perez-Lloret","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jchemneu.2024.102422_bib40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1021\/acsmedchemlett.3c00175","article-title":"Discovery of [(11)C]MK-8056: a selective PET imaging agent for the study of mGluR(2) negative allosteric modulators","volume":"14","author":"Perkins","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jchemneu.2024.102422_bib41","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson's disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib42","first-page":"1088","article-title":"A randomized, double-blind, controlled phase II study of Foliglurax in Parkinson's disease","volume":"37","author":"Rascol","year":"2022"},{"issue":"Pt 3","key":"10.1016\/j.jchemneu.2024.102422_bib43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/brain\/121.3.527","article-title":"Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia","volume":"121","author":"Rascol","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.jchemneu.2024.102422_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cne.20538","volume":"487","author":"Richards","year":"2005","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.neuropharm.2007.08.009","article-title":"Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias","volume":"54","author":"Samadi","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jchemneu.2024.102422_bib46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/NEN.0b013e31819cabe4","article-title":"Metabotropic glutamate receptor II in the brains of Parkinsonian patients","volume":"68","author":"Samadi","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/mol.53.2.228","article-title":"In vitro binding characteristics of a new selective group II metabotropic glutamate receptor radioligand, [3H]LY354740, in rat brain","volume":"53","author":"Schaffhauser","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib48","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jchemneu.2024.102422_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172957","article-title":"Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset","volume":"873","author":"Sid-Otmane","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib50","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jchemneu.2024.102422_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","article-title":"6-Hydroxy-dopamine induced degeneration of central monoamine neurons","volume":"5","author":"Ungerstedt","year":"1968","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jchemneu.2024.102422_bib52","first-page":"453","article-title":"3H] LY341495 binding to group II metabotropic glutamate receptors in rat brain","volume":"298","author":"Wright","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jchemneu.2024.102422_bib53","doi-asserted-by":"crossref","first-page":"11469","DOI":"10.1021\/acs.jmedchem.9b01991","article-title":"Identification and development of a new positron emission tomography ligand 4-(2-Fluoro-4-[11C]methoxyphenyl)-5-((1-methyl-1H-pyrazol-3-yl)methoxy)picolinamide for imaging metabotropic glutamate receptor subtype 2 (mGlu2)","volume":"63","author":"Yamasaki","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jchemneu.2024.102422_bib54","doi-asserted-by":"crossref","first-page":"9939","DOI":"10.1021\/acs.jmedchem.2c00593","article-title":"Design, synthesis, and characterization of [(18)F]mG2P026 as a high-contrast PET imaging ligand for metabotropic glutamate receptor 2","volume":"65","author":"Yuan","year":"2022","journal-title":"J. Med Chem."},{"key":"10.1016\/j.jchemneu.2024.102422_bib55","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1021\/acs.jmedchem.1c02004","article-title":"Synthesis and characterization of 5-(2-Fluoro-4-[(11)C]methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridine-7-carboxamide as a PET imaging ligand for metabotropic glutamate receptor 2","volume":"65","author":"Yuan","year":"2022","journal-title":"J. Med Chem."},{"key":"10.1016\/j.jchemneu.2024.102422_bib56","series-title":"Metabotropic Glutamate Receptor Technologies","first-page":"23","article-title":"Positron emission tomography (PET) imaging of metabotropic glutamate receptor subtype 2 (mGlu2) based on a negative allosteric modulator radioligand","author":"Zhang","year":"2021"},{"key":"10.1016\/j.jchemneu.2024.102422_bib57","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0924-977X(02)00108-6","article-title":"Architectonics of the human cerebral cortex and transmitter receptor fingerprints: reconciling functional neuroanatomy and neurochemistry","volume":"12","author":"Zilles","year":"2002","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Journal of Chemical Neuroanatomy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891061824000358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891061824000358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T14:46:25Z","timestamp":1721400385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891061824000358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":57,"alternative-id":["S0891061824000358"],"URL":"https:\/\/doi.org\/10.1016\/j.jchemneu.2024.102422","relation":{},"ISSN":["0891-0618"],"issn-type":[{"type":"print","value":"0891-0618"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoradiographic labelling of metabotropic glutamate type 2\/3 receptors in the hemi-parkinsonian rat brain","name":"articletitle","label":"Article Title"},{"value":"Journal of Chemical Neuroanatomy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchemneu.2024.102422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102422"}}